Patents by Inventor Ruchi Bajpai

Ruchi Bajpai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9598670
    Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: March 21, 2017
    Assignee: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Patent number: 9157061
    Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: October 13, 2015
    Assignee: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Publication number: 20150152380
    Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 4, 2015
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Patent number: 8178349
    Abstract: This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 15, 2012
    Assignee: Burnham Institute For Medical Research
    Inventors: Alexy Terskikh, Ruchi Bajpai
  • Publication number: 20120034618
    Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Application
    Filed: June 20, 2011
    Publication date: February 9, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Patent number: 7964402
    Abstract: We used Accutase™, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, Accutase treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with Accutase to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. Accutase-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: June 21, 2011
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Publication number: 20080254004
    Abstract: This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders.
    Type: Application
    Filed: February 9, 2006
    Publication date: October 16, 2008
    Applicant: Burnham Institute For Medical Research
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Publication number: 20080058221
    Abstract: We used Accutase™, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, Accutase treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with Accutase to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. Accutase-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Application
    Filed: May 24, 2007
    Publication date: March 6, 2008
    Inventors: Alexey Terskikh, Ruchi Bajpai